Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
3(19%)
Results Posted
0%(0 trials)
Terminated
2(13%)

Phase Distribution

Ph phase_3
3
19%
Ph phase_2
4
25%
Ph not_applicable
1
6%
Ph phase_1
8
50%

Phase Distribution

8

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
8(50.0%)
Phase 2Efficacy & side effects
4(25.0%)
Phase 3Large-scale testing
3(18.8%)
N/ANon-phased studies
1(6.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

3

trials recruiting

Total Trials

16

all time

Status Distribution
Active(4)
Completed(10)
Terminated(2)

Detailed Status

Completed10
Recruiting2
Terminated2
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
3
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (50.0%)
Phase 24 (25.0%)
Phase 33 (18.8%)
N/A1 (6.3%)

Trials by Status

not_yet_recruiting16%
recruiting213%
active_not_recruiting16%
completed1063%
terminated213%

Recent Activity

3 active trials
Showing 5 of 16
active_not_recruitingphase_2

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

NCT06492915
not_yet_recruitingphase_3

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT07445295
completedphase_2

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

NCT05497843
terminatedphase_2

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

NCT05336721
completedphase_3

Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer

NCT04830813
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT06492915Phase 2

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Active Not Recruiting
NCT07445295Phase 3

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Not Yet Recruiting
NCT05497843Phase 2

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Completed
NCT05336721Phase 2

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Terminated
NCT04830813Phase 3

Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer

Completed
NCT04921527Phase 3

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

Recruiting
NCT05271292Phase 1

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Recruiting
NCT05371899Not Applicable

Mass Balance Study of [14C]Chiauranib

Completed
NCT03216343Phase 1

Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

Completed
NCT05346601Phase 1

Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers

Completed
NCT03974243Phase 1

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Completed
NCT03245190Phase 1

Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma

Completed
NCT03901118Phase 2

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Completed
NCT03166891Phase 1

Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

Completed
NCT03074825Phase 1

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

Terminated
NCT02122809Phase 1

Phase I Study of Chiauranib in Patients With Advanced Solid Tumors

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16